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Pyrazinamide (PZA) is an important first-line antituberculosis drug because of its sterilizing activity against
semidormant tubercle bacilli. In spite of its very high in vivo activity, its in vitro activity is not apparent unless
an acidic environment is available, which makes PZA susceptibility testing difficult by conventional methods.
The present study was, therefore, planned to assess the performance of the colorimetric BacT/ALERT 3D
system and compare the results with those from conventional tests, i.e., the Lo¨wenstein-Jensen (LJ) proportion
method (pH 4.85) and Wayne’s pyrazinamidase (PZase) assay, using 107 clinical isolates. The concordance
among all of these tests was 89.71% after the first round of testing and reached 92.52% after resolution of the
discordant results by retesting. Prolonged incubation of the PZase tube for up to 10 days was found to increase
the specificity of the PZase test. The concordances between LJ proportion and BacT/ALERT 3D, LJ proportion
and the PZase assay, and BacT/ALERT 3D and the PZase assay were found to be 99.06%, 93.46%, and 92.52%,
respectively. Using the LJ results as the gold standard, the sensitivities of BacT/ALERT 3D and the PZase
assay were 100 and 82.85%, respectively, while the specificity was 98.61% for both of the tests. The difference
between the sensitivities of BacT/ALERT 3D and the PZase assay was significant (P  0.025). The mean
turnaround times for the detection of resistant and susceptible results by BacT/ALERT 3D were 8.04 and 11.32
days, respectively. While the major limitations associated with the PZase assay and the LJ proportion method
are lower sensitivity in previously treated patients and a longer time requirement, respectively, the BacT/
ALERT 3D system was found to be rapid, highly sensitive, and specific.
Pyrazinamide (PZA) is a nicotinamide analog which is used
as a frontline drug to treat tuberculosis. PZA has a special
place in modern tuberculosis therapy, as it appears to kill a
population of semidormant tubercle bacilli persisting in the
body (22). The addition of PZA to the favored short-course
regimen of isoniazid plus rifampin has facilitated shortening of
the treatment duration from 9 months to 6 months. In spite of
this remarkable role of PZA, it still remains a paradox because
of its incompletely understood mode of action (35–39), which
is also reflected in the difficult procedures for its susceptibility
testing (11, 13, 40).
Multidrug-resistant strains of Mycobacterium tuberculosis
have been emerging worldwide in both high- and low-income
countries. The need for rapid methods of the diagnosis and
determination of drug susceptibility is particularly important.
While the procedures for susceptibility testing of the most of
the first-line and second-line drugs have been well standard-
ized in both liquid and solid media (6), the main problem with
the susceptibility testing of PZA is the requirement of acidic
pH for PZA activity (8, 16, 20, 26, 28).
The difficulty in obtaining PZA susceptibility results in acidic
media by routinely used procedures for some M. tuberculosis
strains makes the detection of pyrazinamidase (PZase) activity
an interesting alternative to the conventional procedures (15,
19). This assay detects the presence of active PZase enzyme by
the hydrolysis of PZA to pyrazinoic acid as evidenced by a
color change (33).
The application of various rapid phenotypic methods such as
radiometric BACTEC 460 (12), fluorimetric Mycobacteria
Growth Indicator Tube (MGIT) 960 (Becton Dickinson) (1,
23), ESP Culture System II (Trek Diagnostic Systems, West-
lake, OH) (18), and the colorimetric BacT/ALERT 3D system
(bioMe´rieux Inc., Durham, NC), previously designated MB/
BACT (Organon Teknika, Boxtels, The Netherlands) (2, 4),
has been reported to be useful for rapid and reliable suscep-
tibility testing of M. tuberculosis isolates. The performances of
these systems have been evaluated in comparison to one an-
other as well as with the conventional proportion method for
first-line drugs, including rifampin, isoniazid, ethambutol, and
streptomycin (1–4, 12, 17, 18, 21, 23, 25, 34). A similar expe-
rience for PZA in MB/BacT is limited (2, 4, 24, 29). So far,
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there has been no study comparing the performances of the
Lo¨wenstein-Jensen (LJ) proportion method, Wayne’s enzy-
matic PZase assay, and the BacT/ALERT 3D system for PZA
susceptibility testing. The present study was, therefore, under-
taken to evaluate the BacT/ALERT 3D system and compare
the results with those of the Lo¨wenstein-Jensen (LJ) propor-
tion method and the enzymatic PZase assay for PZA suscep-
tibility testing of M. tuberculosis.
MATERIALS AND METHODS
M. tuberculosis isolates. A total of 107 biochemically characterized clinical
isolates of M. tuberculosis (32) with known LJ proportion sensitivity testing
results (36 resistant and 71 susceptible to PZA) were included in this study.
These clinical isolates were from the sputum specimens of tuberculosis patients
collected during the period of March 2004 to August 2005 from different parts of
India and belonged to treated as well as untreated patients (78 previously treated
and 29 untreated cases).
The PZA-susceptible reference strain M. tuberculosis H37Rv (TMC-102) was
obtained from the Mycobacterial Repository Center at the National JALMA
Institute for Leprosy and Other Mycobacterial Diseases (ICMR), Agra, India.
These isolates were subcultured on LJ medium.
PZA susceptibility testing by the LJ proportion method. For this method,
dilutions prepared from the standard (1 mg/ml), clump-free suspension (13) were
inoculated onto LJ medium as described previously (6, 30). An isolate was
considered resistant if it yielded a growth equal to or more than 1% at a PZA
concentration of 100 g/ml compared to the drug-free acid control (pH 4.85)
(30). For every batch of medium and every round of susceptibility testing, one
susceptible and one resistant control were used to ensure reproducibility.
PZA susceptibility testing by the BacT/ALERT 3D system. In this method, the
Mycobacteria Process bottles with 7H9 medium were supplemented with recon-
stitution fluid (oleic acid, glycerol, and bovine serum albumin) and 2 ml of
acidifying solution (0.067 M KH2PO4) was added to each bottle. PZA (Sigma)
stock solution was added to the bottles so as to attain a final concentration of 100
g/ml. Equal amounts of sterile distilled water were added to the drug-free
control bottles. A 0.5-ml bacterial suspension adjusted to a 0.5 McFarland tur-
bidity was used as an inoculum for the drug-containing bottles, and a 100
diluted suspension was inoculated in the drug-free control bottles (1% propor-
tional control). The bottles were loaded in the instrument’s incubation module at
37°C. If the bottle containing PZA flagged positive at the same time as or before
the bottle containing the drug-free proportional control, the isolate was consid-
ered resistant. The test was considered valid only if the results of the propor-
tional growth control were available within 20 days. Reference strain M. tuber-
culosis H37Rv was used as the susceptible control, and isolates found to be PZase
negative and resistant by LJ proportion sensitivity testing were used as the
resistant controls. All positive bottles were smeared and stained by the Ziehl-
Neelsen method to confirm the presence of acid-fast bacilli.
PZase assay. The PZase assay was done as described by Wayne (33), with
slight modifications briefly described below.
(i) Preparation of modified PZase agar. 7H9 broth base (2.35 g) (Difco) was
dissolved in 450 ml water, to which 2 ml glycerol (instead of sodium pyruvate,
which gives yellowish tint to the medium), PZA (Sigma) at a final concentration
of 400 g/ml (instead of 100 g/ml as described previously [33]), and 1.5%
agarose were added. Four-milliliter aliquots of this melted PZase agar were
distributed in glass tubes and autoclaved. The tubes were then kept upright to
form the butts. Modifications in medium formulation for the PZase assay were
basically aimed at preparing the semitransparent media with higher PZA con-
centrations so that even a faint pink band could be detected easily against white
background.
(ii) Inoculation of modified PZase agar and interpretation. A heavy loopful (8
to 10 mg) of actively growing culture was carefully inoculated on the surface of
the modified PZase agar medium and incubated at 37°C for 4 days. One milliliter
of ferrous ammonium sulfate (1%) was added to each tube after incubation and
observed for an initial 4 h for the appearance of a pink band (positive) in the
subsurface agar. PZA-resistant isolates of M. tuberculosis found to be negative by
the PZase test earlier were used as negative controls, and the PZA-susceptible
strain M. tuberculosis H37Rv was used as positive control with this modified
PZase medium. The PZase assay was interpreted independently by two observers
who did not know the results of PZA susceptibility testing by either the LJ
proportion method or the BacT/ALERT 3D system.
Resolution of discordance. Isolates with discordant result for any of the three
tests were retested in order to resolve the discordance.
Analysis of data. Using LJ proportional susceptibility testing results as the gold
standard (9), the performance parameters of the BacT/ALERT 3D system and
the PZase assay were determined as recommended by Enarson et al. (10) and
also as described by Barreto et al. (2). Fisher’s exact test (two-tailed) at a 5%
level of significance was applied to determine the statistical significance of the
difference between the sensitivities of both of these tests.
RESULTS
All of the controls yielded reproducible results by all
three methods. The results of 107 test isolates by different
methods/systems showed that 67 isolates were susceptible
and 29 were resistant to PZA by all three methods whereas
11 isolates showed discordant results (Table 1). Among the
isolates with discordant results, six were resistant by LJ and
the BacT/ALERT 3D system but susceptible by the PZase
assay. One isolate was resistant by the LJ proportion
method only, whereas another was resistant by BacT/
ALERT 3D only. Three isolates were resistant by the PZase
assay only.
Isolates with discordant results were retested, and the results
of the repeat test are shown in Table 2. Upon repeat testing,
one isolate initially found to be resistant by the LJ proportion
method only turned susceptible while another isolate resistant
by the BacT/ALERT 3D system only was again found to be
resistant at 100 g/ml but susceptible at 300 g/ml. Two iso-
lates which were PZase negative in the first test became pos-
itive when incubated for 10 days in the repeat test, whereas a
third isolate still remained negative. Six PZase-positive isolates
with a resistant phenotype on LJ medium as well as BacT/
ALERT 3D were indeed found to be the cases of a mixed
population of resistant bacilli among a predominantly (45 to
80%) susceptible population.
Using repeat LJ results as the gold standard, the perfor-
mance parameters of the other two systems were determined
(Table 3). The sensitivity, specificity, and accuracy of BacT/
ALERT 3D were 100% (35/35), 98.61% (71/72), and 99.06%
(106/107), respectively, and those for the PZase assay were
82.85% (29/35), 98.61% (71/72), and 93.46% (100/107), respec-
tively (Table 3). The difference between the sensitivities of
BacT/ALERT 3D and the PZase assay was statistically signif-
icant (P  0.025), whereas the specificities of both tests were
equally high. The overall concordance among all three meth-
ods was 89.71% (96/107) after the first round of testing and
increased to 92.52% (99/107) after retesting.
TABLE 1. Comparison of PZA susceptibility testing results for LJ
proportion method, BacT/ALERT 3D system, and PZase assay
Test Result for indicated testa
LJ proportion method S S S R R R
BacT/ALERT 3D system S S R S R R
PZase assay S R S S S R
No. of isolates with results 67 3 1 1 6 29
a S, susceptible; R, resistant.
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DISCUSSION
PZA is a frontline antituberculous drug with sterilizing ac-
tivity against semidormant tubercle bacilli. Susceptibility test-
ing of M. tuberculosis against PZA is difficult because the drug
is active only in a relatively low-pH environment which causes
nearly 50% inhibition in the colony count of M. tuberculosis
and a considerable reduction in colony size compared with a
neutral-pH environment (28). In several studies, a lack of
PZase activity has been observed to be correlated with PZA
resistance (5, 19, 21, 31). Therefore, the detection of PZase
activity at neutral pH by Wayne’s PZase assay has been used
for PZA susceptibility testing. However, the detection of weak
PZase activity by this assay is difficult because of a very faint
band in some isolates in conventional PZase agar medium,
which has been overcome by modifying the assay.
The major utility of the PZase assay lies in its high specific-
ity, as observed in our study (71/72, 98.61%) and as reported by
others as well (17, 31). In our study, the sensitivity of the PZase
assay was 82.85% (29/35). Various levels of sensitivity of the
PZase assay in different studies have been reported. Trivedi
and Desai (31), Davies et al. (7), and Krishnamurthy et al. (17)
have reported 96% (170/177), 79% (15/19), and 83% (5/6)
sensitivities, respectively.
PZA-resistant isolates with a positive PZase test have been
reported in previous studies by several authors (5, 7, 17, 31).
This is correlated with the observation that resistance to
PZA has been described for M. tuberculosis isolates with
normal PZase activity encoded by the wild-type pncA gene,
thus constituting an inherent limitation of the test (14, 27,
38). In the present study also, 6 out of 35 PZA-resistant
isolates were classified as sensitive by the PZase test. The
presence of PZase activity in these PZA-resistant isolates
could be due to the presence of mixed populations, as con-
firmed by the presence of a 45 to 80% sensitive population in
these isolates observed by CFU on LJ medium. All of these
patients had a history of previous antituberculous treatment.
After analyzing the data of PZA resistance in treated versus
untreated cases, we observed that 42% (33/78) of isolates were
resistant among treated patients whereas this figure was only
6.9% (2/29) for the untreated ones. The specificities of the
PZase assay in these groups were 97.78% (44/45) and 100%
(27/27), respectively. The sensitivity of the PZase assay in iso-
lates from treated cases was 82% (27/33). Considering the
excellent specificity of the PZase assay in both of the groups
but the lower sensitivity among the treated cases, we propose
that the PZase assay should be considered more reliable in the
untreated cases, as very few PZA-resistant isolates are ex-
pected among such patients. Further, a positive PZase assay in
isolates from previously treated patients should be confirmed
by the LJ proportion method or by other suitable phenotypic
methods, such as BacT/ALERT 3D.
The discordance in results could be due to the different
cutoff levels used, i.e., 100 g/ml versus 300 g/ml, or due to
the smaller amount of PZase activity, as seen by positive results
after longer incubation (Table 2). Such an observation for the
PZase assay has also been reported by Kantor et al. (15). It
would be advisable to inoculate two PZase agar tubes simul-
taneously. If the result in one tube remains negative at the end
TABLE 2. Results of repeated tests for discordant results among LJ proportion method, BacT/ALERT 3D system, and PZase assaya
Isolate T/Ub
Result of initial test Result(s) of repeat test
% Resistance
on LJ mediumLJ PMc PZase assay BacTd LJ PM PZase assayafter 4 days
PZase assay
after 10 days BacT
7 T S  S S  ,e R S Nil
21 U S  R S , S NDf Rg Nil
36 U S  S S  , S S Nil
37 T R  S S , S ND S 0.7
42 T S  S S  , S S Nil
74 T R  R R , S ND R 39
76 T R  R R , S ND R 40
79 T R  R R , S ND R 35
92 T R  R R , S ND R 30
103 T R  R R , S ND R 20
104 T R  R R , S ND R 55
a R, resistant; S, susceptible; , positive; , negative.
b T, treated case; U, untreated case.
c LJ PM, Lo¨wenstein-Jensen proportion method.
d BacT, PZA susceptibility testing by the BacT/ALERT 3D system at a 100-g/ml concentration.
e Negative at the end of 20 days also.
f ND, not done if the tube at 4 days was positive.
g Resistant to a PZA concentration of 100 g/ml but susceptible at 300 g/ml.
TABLE 3. Performance parameters of BacT/ALERT 3D system
and PZase assay after resolution of the discordant results
Performance
parameter
% witha:
BacT/ALERT 3D
system PZase assay
Sensitivity 100 (35/35) 82.85 (29/35)
Specificity 98.61 (71/72) 95.83 (69/72)
Accuracy 99.06 (106/107) 91.58 (98/107)
Predictive value for
resistance (PPV)b
97.22 (35/36) 90.63 (29/32)
Predictive value for
susceptibility (NPV)c
100 (71/71) 92.0 (69/75)
a Values in parentheses are the number of isolates; the first number represents
the number of isolates detected for each parameter, and the second number
represents the total number of isolates tested.
b PPV, positive predictive value.
c NPV, negative predictive value.
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of 4 days, another tube should be held for 10 days in order to
increase the specificity and predictive value for resistance. This
will not, however, compromise the sensitivity of the test as the
isolates resistant to PZA remain negative even after longer
incubation. However, adequate data and more studies are re-
quired to make such a generalization or recommendation.
The sensitivity and the specificity of the BacT/ALERT 3D
system in the present study are comparable to those in earlier
reports (2, 4, 29). The BacT/ALERT 3D system was shown to
be rapid as results were available after 10.92 (median, 10.32)
days on average (range, 2.57 to 20.29 days). All of the isolates
grew well, except one which was found to be susceptible at the
end of 25 days by this system. The mean time required for
generation of resistant results (8.04 days) was considerably
lower than that for susceptible results (11.32) and was compa-
rable to that reported in other studies using the MB/BacT
system (4) as well as other nonradiometric systems, such as
BACTEC MGIT 960 (1, 23). The delay in results for suscep-
tible isolates in our study might be due to the employment of
a 1:100-diluted inoculum for drug-free controls in accordance
with the principle of the proportion method, which is also used
as a criterion of resistance in LJ medium. Moreover, the time
reported by the earlier studies with either BACTEC 460 or
other nonradiometric systems did not include the time re-
quired for flagging the seed bottle positive before it is used as
an inoculum. In our study, we prepared inocula from actively
growing LJ cultures. However, as reported by Bemer et al. (4),
the use of the undiluted growth control is particularly recom-
mended in the case of PZA, as acidified medium delays the
time of detection of susceptible results. In that case, an isolate
is interpreted as drug resistant when a drug-containing test
bottle gives a positive signal no later than 3.5 days after the
undiluted control has flagged positive (4, 34).
Rapid and reliable susceptibility testing for PZA is very
important. Since PZA is administered in the early intensive
phase of antituberculosis treatment, any method giving rapid
results of PZA susceptibility testing has its own merit. Consid-
ering the requirement of long times for the LJ proportion
method as well as the inability of some isolates to grow on
acidified medium (28, 31), the PZase assay, in spite of its being
relatively less sensitive, appears to be a useful screening
method for PZA susceptibility testing. However, considering
the possibility of a mixed population of resistant and sensitive
bacilli in isolates from previously treated patients, a positive
result in such a case should be confirmed either by the pro-
portion method or by any other rapid method, if available.
Isolates negative at 4 days should be incubated for 10 days
before it is concluded that they are negative. Further efforts
may be made to convert this method into some semiquantita-
tive technique. The BacT/ALERT 3D system, in addition to its
higher sensitivity and specificity, can offer the extra advantages
of rapidity and a better success rate; however, a higher running
cost and expensive equipment are its limitations.
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